SEC Company Response from Karyopharm Therapeutics (KPTI) — May 12, 2026
Karyopharm Therapeutics Inc.
Date: May 12, 2026 · CIK: 0001503802 · Accession: 0001193125-26-219351
AI Filing Summary & Sentiment
File numbers found in text: 333-295535
Show Raw Text
CORRESP 1 filename1.htm CORRESP May 12, 2026 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Alan Campbell Re: Karyopharm Therapeutics Inc. Registration Statement on Form S-3 Filed May 4, 2026 File No. 333-295535 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Karyopharm Therapeutics Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-295535), so that it may become effective at 4:30 p.m., Eastern Time, on May 14, 2026, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff. Very truly yours, KARYOPHARM THERAPEUTICS INC. By: /s/ Michael Mano Name: Michael Mano Title: Executive Vice President, Chief Legal Officer and Secretary cc: Jason Kropp, Sidley Austin LLP Craig Hilts, Sidley Austin LLP